Effets du 3,4-diaminopyridine sur la jonction neuromusculaire murine

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Avatar du membre

Auteur du sujet
Messages : 5235
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Zodiaque :
Âge : 61
Contact :

Effets du 3,4-diaminopyridine sur la jonction neuromusculaire murine

Message par Pboulanger » 19 août 2016 16:47


Lu sur http://onlinelibrary.wiley.com/wol1/doi ... 8/abstract
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Effect of 3,4-diaminopyridine at the murine neuromuscular junction
Fiona Ng BS, Diana C. Lee BS, Leah A. Schrumpf BS, Mary E. Mazurek BS, Victoria Lee Lo BS, Sharleen K. Gill BS andRicardo A. Maselli MD*
Version of Record online: 17 AUG 2016
DOI: 10.1002/mus.25208

  • Introduction:

    We investigated the effects of 3,4-diaminopyridine (3,4-DAP) and its acetylated metabolite, N-(4-amino-pyridin-3-yl) acetamide (3-Ac), at the mammalian neuromuscular junction.
  • Methods:

    Quantal release of acetylcholine was studied in diaphragm muscles of mice, using in vitro intracellular microelectrode recordings.
  • Results:

    Under conditions of low probability of release, 3,4-DAP produced a 1,000% increase in quantal release, but 3-Ac had no effect. Under conditions of normal probability of release, the effect of 3,4-DAP was modest and limited by concurrent depletion of synaptic vesicles, especially with high concentrations of 3,4-DAP and high frequencies of nerve stimulation.
  • Conclusions:

    These findings predict 3,4-DAP is most effective in conditions with low probability of quantal release, such as Lambert-Eaton myasthenic syndrome. A beneficial effect is also expected in disorders of neuromuscular transmission in which the effect of 3,4-DAP on quantal release is not limited by depletion of synaptic vesicles, such as postsynaptic congenital myasthenic syndromes.
Muscle Nerve, 2016



Retourner vers « Informations »